Physician

Aditi Swami, M.D.

According to 2025 Medicare claims, Aditi Swami, M.D. (NPI: 1386851566) practices infectious disease in the Sherman-Denison, TX market, with the plurality of this provider's patient population coming from Grayson, TX. This provider's primary affiliated billing organization is ADITI SWAMI PA (NPI: 1881947026; TIN: 460578674) and primary practice location at 75020-4584. Swami is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Swami's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 993 traditional Medicare patients, billed 21,672 HCPCS/CPT codes, and received $566,585 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,437 prescription claims across 339 beneficiaries totaling $457,576 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). 2019 DME data shows 40 claims. Open Payments data shows 105 records totaling $57,234. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $1,530,085 to $457,576. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,033	24,286	$603,331
2016	1,126	17,877	$617,488
2017	1,291	21,306	$714,701
2018	1,311	32,537	$922,367
2019	1,286	38,653	$786,600
2020	1,321	22,658	$831,010
2021	1,192	19,534	$702,935
2022	1,009	21,118	$704,638
2023	1,076	44,861	$756,862
2024	993	21,672	$566,585

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	272	848	$1,530,085
2016	405	1,227	$1,969,936
2017	419	1,157	$1,638,568
2018	418	1,221	$1,461,921
2019	354	1,390	$864,609
2020	329	1,442	$705,689
2021	286	1,334	$748,641
2022	349	1,588	$1,031,256
2023	344	1,365	$830,971
2024	339	1,437	$457,576

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	25	$3,258
2016	N/R	36	$12,112
2017	N/R	40	$10,829
2018	N/R	26	$3,549
2019	N/R	40	$12,161
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	588	707	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	304	840	$72
99221	Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes	186	226	$66
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	427	637	$61
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	673	4,184	$39

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	27	810	$105,847
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	21	630	$88,630
Tivicay	Dolutegravir Sodium	22	660	$68,478
Daptomycin	Daptomycin	81	539	$44,096
Etravirine	Etravirine	11	330	$12,458

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$177	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	97	$57,057	Dompe Farmaceutici S.p.A.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aditi Swami, M.D.?

Tedicare shows public-source Medicare data for Aditi Swami, M.D. (NPI 1386851566), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aditi Swami, M.D. have ACO affiliation data?

Aditi Swami, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Aditi Swami, M.D.?

Aditi Swami, M.D. is linked to ADITI SWAMI PA (billing NPI 1881947026) in the available physician profile data.

Does Aditi Swami, M.D. have Open Payments data?

Aditi Swami, M.D. has 105 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.